JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3876
Dimensional Emerging Markets Value ETF
DFEV
$2.2B
| $987K | ﹤0.01% |
42,211
+8,316
| +25% | +$195K |
2022 Q4
1 quarter
|
|
3877
Philips
PHG
$23.5B
| $986K | ﹤0.01% |
62,782
-90,968
| -59% | -$1.31M |
2013 Q2
39 quarters
|
|
3878
CALL
SoFi Technologies
SOFI
$20.2B
| $986K | ﹤0.01% |
162,400
-837,200
| -84% | -$5.08M |
2021 Q2
7 quarters
|
|
|
EVEN
3879
DELISTED
Direxion Daily S&P 500 Equal Weight Bull 2X Shares
EVEN
| $983K | ﹤0.01% |
50,000
| – | – |
2022 Q1
4 quarters
|
|
3880
iShares Core Conservative Allocation ETF
AOK
$820M
| $982K | ﹤0.01% |
28,122
+26,822
| +2,063% | +$928K |
2015 Q3
30 quarters
|
|
3881
MasterCraft Boat Holdings
MCFT
$473M
| $982K | ﹤0.01% |
32,278
+9,925
| +44% | +$308K |
2017 Q4
21 quarters
|
|
|
FTCH
3882
PUT
DELISTED
Farfetch Limited Class A Ordinary Shares
FTCH
| $982K | ﹤0.01% |
200,000
| – | – |
2022 Q4
1 quarter
|
|
|
YMAB
3883
DELISTED
Y-mAbs Therapeutics
YMAB
| $979K | ﹤0.01% |
195,435
+162,752
| +498% | +$665K |
2018 Q3
18 quarters
|
|
3884
iShares ESG Aware 1-5 Year USD Corporate Bond ETF
SUSB
$1.29B
| $966K | ﹤0.01% |
40,137
+28,991
| +260% | +$694K |
2021 Q2
7 quarters
|
|
|
NYXH
3885
Nyxoah
NYXH
$145M
| $965K | ﹤0.01% |
+137,891
| New | +$773K |
2023 Q1
0 quarters
|
|
3886
Tilray
TLRY
$548M
| $962K | ﹤0.01% |
38,061
+4,982
| +15% | +$142K |
2018 Q3
18 quarters
|
|
3887
Immunovant
IMVT
$6.62B
| $961K | ﹤0.01% |
61,992
+11,578
| +23% | +$201K |
2020 Q1
12 quarters
|
|
3888
iShares Russell Top 200 Growth ETF
IWY
$16.9B
| $960K | ﹤0.01% |
6,908
+808
| +13% | +$105K |
2019 Q3
14 quarters
|
|
|
SHYF
3889
DELISTED
The Shyft Group
SHYF
| $958K | ﹤0.01% |
42,046
+141
| +0.3% | +$3.95K |
2016 Q4
25 quarters
|
|
3890
Phathom Pharmaceuticals
PHAT
$551M
| $954K | ﹤0.01% |
133,587
+4,438
| +3% | +$39K |
2019 Q4
13 quarters
|
|
3891
Stoke Therapeutics
STOK
$1.57B
| $954K | ﹤0.01% |
114,467
+90,608
| +380% | +$817K |
2019 Q3
14 quarters
|
|
3892
PUT
Warby Parker
WRBY
$3.13B
| $953K | ﹤0.01% |
90,000
| – | – |
2022 Q1
4 quarters
|
|
|
LPRO
3893
DELISTED
Open Lending Corp
LPRO
| $952K | ﹤0.01% |
135,238
+25,662
| +23% | +$200K |
2020 Q4
9 quarters
|
|
3894
Waterstone Financial
WSBF
$353M
| $952K | ﹤0.01% |
62,904
-17,448
| -22% | -$281K |
2015 Q3
30 quarters
|
|
3895
PUT
Baidu
BIDU
$29B
| $951K | ﹤0.01% |
6,300
-24,500
| -80% | -$3.47M |
2020 Q3
10 quarters
|
|
3896
Corsair Gaming
CRSR
$1.47B
| $951K | ﹤0.01% |
51,844
+12,091
| +30% | +$197K |
2020 Q3
10 quarters
|
|
3897
CALL
Edwards Lifesciences
EW
$49.4B
| $951K | ﹤0.01% |
11,500
| – | – |
2022 Q1
4 quarters
|
|
|
TELL
3898
DELISTED
Tellurian Inc.
TELL
| $949K | ﹤0.01% |
772,554
-345,149
| -31% | -$550K |
2017 Q4
21 quarters
|
|
3899
Aurora
AUR
$11.5B
| $946K | ﹤0.01% |
680,354
+102,305
| +18% | +$151K |
2022 Q2
3 quarters
|
|
3900
Invesco DB Base Metals Fund
DBB
$363M
| $943K | ﹤0.01% |
46,708
+3,180
| +7% | +$65.4K |
2020 Q4
9 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.